Calidi Biotherapeutics (CLDI) Return on Capital Employed (2022 - 2025)
Calidi Biotherapeutics' quarterly Return on Capital Employed came in at 269.58% in Q4 2025, up 208841.0% year-on-year from N/an in Q4 2024, and up 11.54% quarter-over-quarter from 304.76% in Q3 2025.
Calidi Biotherapeutics has reported Return on Capital Employed for 4 years, with the latest figure at 269.58% in Q4 2025.
- For the quarter ending Q4 2025, Return on Capital Employed rose 208841.0% year-over-year to 269.58%; the trailing twelve-month figure through Dec 2025 stood at 269.58% (up 208841.0% YoY), and the FY2025 full-year result was 266.86%, up 56923.0% from the prior year.
- Return on Capital Employed for Q4 2025 stood at 269.58%, up from 304.76% in the prior quarter.
- The five-year high for Return on Capital Employed was 547.57% in Q3 2024, with the low at 2357.99% in Q4 2024.
- Average Return on Capital Employed over 4 years is 220.66%, with a median of 116.82% recorded in 2023.
- Year-over-year, Return on Capital Employed sank 164583 bps in 2024 and jumped 208841 bps in 2025.
- Tracing CLDI's Return on Capital Employed over 4 years: stood at 60.96% in 2022, then sank by 1268 bps to 712.16% in 2023, then plunged by 231 bps to 2357.99% in 2024, then soared by 89 bps to 269.58% in 2025.
- The last three Return on Capital Employed figures came in at 269.58% (Q4 2025), 304.76% (Q3 2025), and 291.46% (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,638,563.89 Bn | 1,638,563.89 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 3 | Legend Biotech | 2,937.00 Bn | 2,936.10 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,282.79 Bn | 2,282.72 Bn | - | - |
| 5 | Akari Therapeutics | 2,169.69 Bn | 2,169.69 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 110.41 Bn | 103.16 Bn | 2.59 Bn | 21.10% |
| 7 | Regeneron Pharmaceuticals | 66.44 Bn | 57.69 Bn | 3.31 Bn | 10.19% |
| 8 | Evaxion A | 65.44 Bn | 65.42 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.53 Bn | 36.52 Bn | 959.66 Mn | 20.34% |
| 10 | Calidi Biotherapeutics | - | - | - | -269.58% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -269.58% |
| Sep 30, 2025 | -304.76% |
| Jun 30, 2025 | -291.46% |
| Mar 31, 2025 | -218.40% |
| Dec 31, 2024 | -2,357.99% |
| Sep 30, 2024 | 547.57% |
| Jun 30, 2024 | 481.99% |
| Mar 31, 2024 | 485.98% |
| Dec 31, 2023 | -712.16% |
| Sep 30, 2023 | -116.82% |
| Jun 30, 2023 | -66.72% |
| Mar 31, 2023 | -107.24% |
| Dec 31, 2022 | 60.96% |